Adaptive Biotechnologies (ADPT) announced that the new Medicare Clinical Laboratory Fee Schedule, CLFS, rate for its next-generation sequencing, NGS,-based clonoSEQ test for minimal – or measurable – residual disease, MRD, assessment is now in effect as of January 1, 2025. The CLFS rate for clonoSEQ was set at $2,007, consistent with the final gapfill rate recommendation for the test.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies price target raised to $9 from $8 at BTIG
- Adaptive Biotechnologies management to meet with BTIG
- Adaptive Biotechnologies announces 65 abstracts to be presented at ASH meeting
- Adaptive Biotechnologies price target raised to $7 from $6 at Piper Sandler
- Adaptive Biotechnologies’ Q3 2024 Financial Performance Overview